RLAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Relay Therapeutics Inc (RLAY) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has positive technical indicators, favorable analyst upgrades, and strong hedge fund interest, making it a compelling opportunity despite weak financial performance.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.111), and RSI_6 at 57.068, indicating a neutral to slightly bullish momentum. Key resistance levels are at 9.159 and 9.6, with support at 7.73 and 7.289. Pre-market price is $8.92, up 1.25%, suggesting positive sentiment.
FDA Breakthrough Therapy designation received.
Hedge funds are significantly increasing their positions (352.49% increase in buying over the last quarter).
Analyst upgrades from Oppenheimer and Wells Fargo with price targets of $14 and $13, respectively, citing potential for data updates and competitive positioning.
Insider selling: R&D President sold 21,581 shares, reducing his holdings by 32.65%.
Weak financial performance in Q3 2025 with a net income drop of -15.84% YoY and EPS decline of -31.75% YoY.
No recent congress trading data or AI Stock Picker/SwingMax signals.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop to -$74.15M (-15.84% YoY), and a decline in EPS to -0.43 (-31.75% YoY). Gross margin remains at 100%, but the lack of revenue and increasing losses are concerning.
Analysts are bullish, with Oppenheimer upgrading the stock to Outperform and setting a $14 price target, citing potential catalysts from upcoming data readouts. Wells Fargo also upgraded the stock to Overweight with a $13 price target, highlighting competitive data updates expected in 2026.
